We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CollabRx Launches Service to Guide Personalized Cancer Treatment: CollabRx ONE
News

CollabRx Launches Service to Guide Personalized Cancer Treatment: CollabRx ONE

CollabRx Launches Service to Guide Personalized Cancer Treatment: CollabRx ONE
News

CollabRx Launches Service to Guide Personalized Cancer Treatment: CollabRx ONE

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CollabRx Launches Service to Guide Personalized Cancer Treatment: CollabRx ONE"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CollabRx, Inc. announced the launch of its new personalized cancer research service, CollabRx ONE, designed to provide physicians with new insights into specific treatment options for their cancer patients.

CollabRx ONE scientists use genomic technologies, including gene expression, SNP analysis, and copy number variation, to analyze biopsies of an individual patient's tumor. The company then conducts in-depth scientific analyses based on proprietary bioinformatics and systems biology techniques to analyze the molecular mechanisms involved, and links the specific cancer to relevant therapies from among thousands of approved pharmaceuticals. A full analysis is presented to the physician for integration into the individual patient treatment plan as appropriate. The program has been piloted with a select group of physicians and patients over the past year.

In his keynote address to Cambridge Healthtech Institute's 16th annual Molecular Medicine Tri-Conference entitled “Using Molecular Medicine to do Therapeutic Development in the Network Age”, CollabRx founder and melanoma survivor Jay M. Tenenbaum, PhD praised the new service as a clear step forward into the future of personalized medicine. “At top medical centers, tests are routinely performed to obtain molecular information on patients' cancers. But, these tests usually screen for the presence of a single gene to affect decisions about a single drug.”

Dr. Tenenbaum explained. “CollabRx ONE scientists look at 15,000 genes simultaneously, in the context of a patient’s full medical situation, and adds advanced technologies to find evidence supporting the potential use of any of the 5,000 approved pharmaceutical therapies and possible investigational compounds. We leave no stone unturned in our quest to assist physicians in finding therapies to treat a patient’s specific disease.”

CollabRx ONE is built on the CollabRx web-based research platform, a unique collaborative research platform that connects scientists with a global network of top research labs, clinicians and contract research organizations. The CollabRx platform enables scientists to leverage the latest technologies, services and scientific information in the quest for the best treatment options. It also drives discovery of new therapies by aggregating the learnings from every patient.

Dr. Tenenbaum explained how the CollabRx platform leverages Health Commons, a nonprofit coalition for sharing research data, standards, technologies and resources in order to better study and treat disease. Health Commons was co-founded by Science Commons, the Public Library of Science, CommerceNet and CollabRx.

Dr. Tenenbaum also described the initiation of the TREAT1000 project, a joint project of CollabRx and Alacris Pharmaceuticals to add full-genome sequencing to the CollabRx ONE offering. By sequencing 1000 genomes of cancer sufferers, TREAT1000 will not only provide potentially life-saving information about individual cancers, but create a compendium of cancer genome information that will inform future research and treatment.
Advertisement